arXiv No Longer Accepts Computer Science Position or Review Papers Due to LLMs
#HackerNews #arXiv #LLMs #ComputerScience #ResearchUpdates #AcademicPublishing
#Tag
arXiv No Longer Accepts Computer Science Position or Review Papers Due to LLMs
#HackerNews #arXiv #LLMs #ComputerScience #ResearchUpdates #AcademicPublishing
· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure
https://thesicktimes.org/2025/09/09/research-updates-september-9/
· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis ( #ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311
https://thesicktimes.org/2025/09/16/research-updates-september-16/
· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10
https://thesicktimes.org/2025/09/02/research-updates-september-2/
· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure
https://thesicktimes.org/2025/09/09/research-updates-september-9/
· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine
https://thesicktimes.org/2025/08/19/research-updates-august-19/
· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10
https://thesicktimes.org/2025/09/02/research-updates-september-2/
· People with myalgic encephalomyelitis ( #MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida
https://thesicktimes.org/2025/08/12/research-updates-august-12/
· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine
https://thesicktimes.org/2025/08/19/research-updates-august-19/
· People with myalgic encephalomyelitis ( #MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida
https://thesicktimes.org/2025/08/12/research-updates-august-12/
· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants
https://thesicktimes.org/2025/08/05/research-updates-august-5/
· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants
https://thesicktimes.org/2025/08/05/research-updates-august-5/
A space for Bonfire maintainers and contributors to communicate